Superiority Standard? Groups Bristle At CMS’ Transcatheter Valve Trial Proposal
This article was originally published in The Gray Sheet
Executive Summary
Some worry that a provision in CMS’ proposed national coverage decision for transcatheter aortic valve replacement devices, which restricts coverage for off-label indications to trials designed to show superiority, signals the agency’s intent to play a more active role in dictating trial designs.
You may also be interested in...
CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population
The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.
Industry Pushes CMS For Details On Centralized Coverage Review Of IDE Trials
Whether they support centralized review or not, device manufacturers want CMS to provide more detail on how the process would work – including timelines, the extent of manufacturer interactions with agency staff, and how appeals would be handled.
CMS Proposes Centralized Review, New Standards For Reimbursement Of IDE Studies
Centralized CMS review for Medicare coverage of device studies, as proposed in the 2014 draft physician fee schedule, could make for a more manageable process. But a provision that IDE trials must be designed to show superiority to be “automatically” covered could face industry pushback.